Arecor Therapeutics plc announced that, in line with the update provided within its Interim Results on 14 September, the Group has taken the decision to increase the number of subjects within its ongoing Phase I clinical trial of ultra-rapid, ultra-concentrated insulin candidate AT278. The increase in the number of subjects within the study, from 32 to 42, will increase the power of the study and, in turn, increase the value of the results for patients with high insulin needs. Results are expected in early 2024.

The trial is a double blind, randomized, crossover study comparing the pharmacokinetic (PK) and pharmacodynamic (PD) profile following a single subcutaneous dose of 0.5 U/Kg of AT278 (500 U/mL) with NovoRapid® (100 U/mL) in 42 people with Type 2 diabetes in a euglycemic clamp setting. In addition, the PK/PD profile following a single subcutaneous dose of 0.5 U/Kg Humulin-R U500® will be evaluated in each of the participants.